欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

csl behring gmbh - lioctocog alfa - hemofilia a - hemostatice - tratamentul și profilaxia hemoragiilor la pacienții cu hemofilie a (deficit congenital de factor viii). afstyla poate fi utilizat pentru toate grupele de vârstă.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

csl behring gmbh - imunoglobulină umană normală (ivig) - purpura, thrombocytopenic, idiopathic; bone marrow transplantation; immunologic deficiency syndromes; guillain-barre syndrome; mucocutaneous lymph node syndrome - seruri imune și imunoglobuline, - terapie de substituție la adulți, și la copii și adolescenți (0-18 ani) în:imunodeficiență primară (idp) sindroame cu afectarea producerea de anticorpi;hipogamaglobulinemie și infecții bacteriene recurente la pacienți cu leucemie limfocitară cronică, la care tratamentul profilactic cu antibiotice a eșuat;hipogamaglobulinemie și infecții bacteriene recurente în platou-faza-multiple-mielom pacienții care nu au răspuns la imunizarea pneumococică;hipogamaglobulinemie la pacienți după transplant alogen hematopoietice-transplantul de celule stem (tcsh);sida congenitală cu infecții bacteriene recurente. imunomodulare la adulți, și la copii și adolescenți (0-18 ani) în:trombocitopenie imună primară (itp), la pacienții cu risc înalt de sângerare sau înainte de o intervenție chirurgicală pentru a corecta numărul de trombocite;sindromul guillain-barré;boala kawasaki;polineuropatie demielinizantă inflamatorie cronică (pdic). numai o experiență limitată privind utilizarea intravenoasă de imunoglobuline la copii cu pdic.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

gilead sciences international limited - cidofovir - retinita citomegalovirusului - antivirale pentru uz sistemic - vistide este indicat pentru tratamentul de retinita cu citomegalovirus la pacienţii cu sindromul imunodeficienţei dobândite (sida) şi fără disfuncţie renală. vistide trebuie utilizat numai atunci când alți agenți sunt considerați necorespunzători.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatita c, cronică - antivirale pentru uz sistemic - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (a se vedea secțiunile 4. 2, 4. 4 și 5.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtricitabină, tenofovir alafenamide, fumarat - infecții cu hiv - antivirale pentru uz sistemic - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (vezi secțiunea 5.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agenți antineoplazici - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirale pentru uz sistemic - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle-cell - agenți antineoplazici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - agenți antineoplazici - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.